噬菌体-抗生素联合策略：对抗耐甲氧西林金黄色葡萄球菌表型的一种替代方法
Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus.
作者信息
Kebriaei Razieh, Lev Katherine, Morrisette Taylor, Stamper Kyle C, Abdul-Mutakabbir Jacinda C, Lehman Susan M, Morales Sandra, Rybak Michael J
机构信息
Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00461-20.
Abstract
Comparative time-kill experiments with bacteriophage (phage) Sb-1 alone and phage-antibiotic combinations (PACs) against two methicillin-resistant (MRSA) strains have shown synergy with both daptomycin-phage and vancomycin-phage combinations. PACs prevented development of phage resistance and demonstrated bactericidal activity for all triple combinations. In addition, the extracellular membrane vesicle (MV) formation and the potential impact of phage on MV suppression were examined. Our results demonstrate the potential of PAC for combating MRSA infections.
摘要
单独使用噬菌体（phage）Sb-1以及噬菌体 - 抗生素组合（PACs）针对两种耐甲氧西林金黄色葡萄球菌（MRSA）菌株进行的比较时间杀菌实验表明，达托霉素 - 噬菌体和万古霉素 - 噬菌体组合均具有协同作用。PACs可防止噬菌体抗性的产生，并对所有三联组合均显示出杀菌活性。此外，还研究了细胞外膜泡（MV）的形成以及噬菌体对MV抑制的潜在影响。我们的结果证明了PACs在对抗MRSA感染方面的潜力。
相似文献
1
Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus.
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00461-20.
2
Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
Microbiol Spectr. 2024 Apr 2;12(4):e0321223. doi: 10.1128/spectrum.03212-23. Epub 2024 Feb 27.
3
Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections : Bacteriophage-Antibiotic Combination.
Microbiol Spectr. 2022 Apr 27;10(2):e0041122. doi: 10.1128/spectrum.00411-22. Epub 2022 Mar 29.
4
Optimization of Phage-Antibiotic Combinations against Staphylococcus aureus Biofilms.
Microbiol Spectr. 2023 Jun 15;11(3):e0491822. doi: 10.1128/spectrum.04918-22. Epub 2023 May 18.
5
Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an Pharmacokinetic/Pharmacodynamic Model.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01863-20.
6
Isolation and evaluation of the efficacy of bacteriophages against multidrug-resistant (MDR), methicillin-resistant (MRSA) and biofilm-producing strains of Staphylococcus aureus recovered from bovine mastitis.
BMC Vet Res. 2022 Nov 17;18(1):406. doi: 10.1186/s12917-022-03501-3.
7
Novel recombinant endolysin ointment with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from wounds and burns.
Arch Microbiol. 2023 Mar 4;205(4):104. doi: 10.1007/s00203-023-03434-x.
8
Surface-enhanced Raman spectroscopy for comparison of biochemical profile of bacteriophage sensitive and resistant methicillin-resistant Staphylococcus aureus (MRSA) strains.
Spectrochim Acta A Mol Biomol Spectrosc. 2024 Apr 5;310:123968. doi: 10.1016/j.saa.2024.123968. Epub 2024 Jan 30.
9
Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations.
Allergy. 2021 Nov;76(11):3446-3458. doi: 10.1111/all.14883. Epub 2021 May 16.
10
Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an simulated endocardial pharmacokinetic/pharmacodynamic model.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0138823. doi: 10.1128/aac.01388-23. Epub 2024 Feb 20.
引用本文的文献
1
Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States.
Antibiotics (Basel). 2025 May 29;14(6):553. doi: 10.3390/antibiotics14060553.
2
Studies and of phage therapy medical products (PTMPs) Targeting Clinical Strains of belonging to the clone ST512.
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0193524. doi: 10.1128/aac.01935-24. Epub 2025 Apr 23.
3
One-Two Punch: Phage-Antibiotic Synergy Observed against by Combining Pleurotin and Phage K.
ACS Omega. 2025 Mar 18;10(12):12026-12036. doi: 10.1021/acsomega.4c09831. eCollection 2025 Apr 1.
4
Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.
AMB Express. 2025 Mar 12;15(1):44. doi: 10.1186/s13568-025-01837-1.
5
Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.
Int J Mol Sci. 2025 Feb 19;26(4):1755. doi: 10.3390/ijms26041755.
6
Phage M198 and Its Therapeutic Potential.
Viruses. 2025 Jan 15;17(1):115. doi: 10.3390/v17010115.
7
Antibiotic Resistance of Strains-Searching for New Antimicrobial Agents-Review.
Pharmaceuticals (Basel). 2025 Jan 11;18(1):81. doi: 10.3390/ph18010081.
8
Temperate phage-antibiotic synergy is widespread-extending to -but varies by phage, host strain, and antibiotic pairing.
mBio. 2025 Feb 5;16(2):e0255924. doi: 10.1128/mbio.02559-24. Epub 2024 Dec 20.
9
resensitization of multidrug-resistant clinical isolates of and through phage-antibiotic synergy.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0074024. doi: 10.1128/aac.00740-24. Epub 2024 Dec 19.
10
Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance.
Front Microbiol. 2024 Jul 5;15:1384164. doi: 10.3389/fmicb.2024.1384164. eCollection 2024.
本文引用的文献
1
Reduced Production of Bacterial Membrane Vesicles Predicts Mortality in ST45/USA600 Methicillin-Resistant Bacteremia.
Antibiotics (Basel). 2019 Dec 18;9(1):2. doi: 10.3390/antibiotics9010002.
2
Silviavirus phage ɸMR003 displays a broad host range against methicillin-resistant Staphylococcus aureus of human origin.
Appl Microbiol Biotechnol. 2019 Sep;103(18):7751-7765. doi: 10.1007/s00253-019-10039-2. Epub 2019 Aug 6.
3
Analysis of Spounaviruses as a Case Study for the Overdue Reclassification of Tailed Phages.
Syst Biol. 2020 Jan 1;69(1):110-123. doi: 10.1093/sysbio/syz036.
4
Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of in a Simulated Pharmacodynamic/Pharmacokinetic Model.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01743-18. Print 2019 Apr.
5
Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Infections.
Viruses. 2019 Jan 21;11(1):88. doi: 10.3390/v11010088.
6
Phage Therapy in the Postantibiotic Era.
Clin Microbiol Rev. 2019 Jan 16;32(2). doi: 10.1128/CMR.00066-18. Print 2019 Apr.
7
Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro.
PLoS One. 2019 Jan 16;14(1):e0209390. doi: 10.1371/journal.pone.0209390. eCollection 2019.
8
Antibiotics Stimulate Formation of Vesicles in in both Phage-Dependent and -Independent Fashions and via Different Routes.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01439-18. Print 2019 Feb.
9
Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections.
Front Microbiol. 2018 Oct 8;9:2419. doi: 10.3389/fmicb.2018.02419. eCollection 2018.
10
Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus.
Int J Antimicrob Agents. 2018 Dec;52(6):842-853. doi: 10.1016/j.ijantimicag.2018.09.006. Epub 2018 Sep 17.
Zotero 插件